Search
CLOSEThe Institute of Chemical Biology (ICB) is the only institute in Greece dedicated to cutting-edge research at the interface of Chemistry and Biology. Through an integrative, interdisciplinary approach, ICB addresses critical challenges in health, drug discovery, and biotechnology.
ICB draws upon and combines the expertise and synergies of its scientific personnel with its state-of-the-art infrastructure, aiming to promote research, education and innovation. ICB by continuously strengthening its uniqueness has succeeded in maximizing its research performance and impact within the national and international research ecosystem.
Newsroom
A review article entitled “Nanoprecipitation- and Nanoemulsification-Based Systems for Nucleic Acid Delivery” was recently published in Current Opinion in Colloid & Interface Science (IF 7.0), with the participation of ICB/NHRF researchers and Dr Evgenia Mitsou as corresponding author.
The article presents recent advances in the development of nanosystems based on nanoprecipitation and nanoemulsification techniques for nucleic acid delivery.
ICB-NHRF is among the partners that will implement the recently approved Twinning Light Project between Greece and Serbia (Ministry of Science, Technological Development and Innovation), entitled “Strengthening capacities and introducing EU practices for sustainable operation and management of the Bio4 Campus”. The project will be implemented under the Annual Action Plan 2022 for Serbia, European Integration Facility (Twinning No.: SR 22 IPA SO 02 25 – Publication EuropeAid/185518/DD/ACT/RS). In Greece, the project is coordinated by the Center of International and European Economic Law and, in addition to the NHRF (scientific coordinator: Dr. E. Gonos, Director of ICB-NHRF), the Biomedical Sciences Research Center “Alexander Fleming” and the National Observatory of Athens are also participating.
Strategic research pillars
ICB is unique in Greece in Drug research employing a comprehensive integrated approach encompassing all the stages of Drug discovery (structural biology, design, synthesis, biological evaluation in vitro, ex vivo and in vivo, development of nanocarriers for effective delivery) combined with translational research (collaboration with clinicians, biomarker, big data analysis).
ICB applies a combination of holistic chemical, biological and computational technologies (genomics, epigenomics, proteomics, transcriptomics and metabolomics) to characterize a wide range of samples, to study the mechanism of disease onset and progression and the efficacy/toxicity of drugs and other therapeutic approaches, and for the discovery of biomarkers related to environmental exposure, population heterogeneity, disease pathogenesis and development of drug resistance.
ICB applies biotechnological approaches, nanotechnology and green chemistry to produce compounds and nanocarriers with applications in food, pharmaceuticals, cosmetics and chemicals.
Click on a pillar for more information
Research Infrastructure & Services
ICB has state-of-the-art scientific equipment and is currently considered one of the best equipped research institutes in Greece, particularly in the fields of Nuclear Magnetic Resonance (NMR), Mass Spectrometry (MS) and X-ray Protein Crystallography.
ICB together with the TPCI, operate a large set of advanced instrumentation, acquired through funding from the European Union – NextGenerationEU, co-financed by national resources and the European Investment Bank, within the framework of the National Recovery and Resilience Plan “Greece 2.0”.
An integral part of ICB’s activities is the provision of specialized services to research and technology centers, universities, health institutions and industries both in the country and abroad.
ICB researchers, utilizing their expertise and the Institute’s state-of-the-art infrastructure, provide scientific services in selected application areas to academic institutions, health institutions (hospitals) and the private sector (Pharmaceutical Industry, Chemical, Food & Cosmetics Industry).